{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "GBp", "marketState": "CLOSED", "regularMarketChangePercent": 0.0, "regularMarketPrice": 15.0, "exchange": "LSE", "shortName": "BIVICTRIX THERAPEUTICS PLC ORD ", "longName": "BiVictriX Therapeutics Plc", "messageBoardId": "finmb_417339681", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketTime": 1683709169, "earningsTimestamp": 1680156000, "earningsTimestampStart": 1680156000, "earningsTimestampEnd": 1680156000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.04, "epsForward": -25.8, "epsCurrentYear": -17.8, "priceEpsCurrentYear": -0.84269667, "sharesOutstanding": 66115200, "bookValue": 0.06, "fiftyDayAverage": 15.63, "fiftyDayAverageChange": -0.6300001, "fiftyDayAverageChangePercent": -0.04030711, "twoHundredDayAverage": 17.57485, "twoHundredDayAverageChange": -2.57485, "twoHundredDayAverageChangePercent": -0.14650765, "marketCap": 9917280, "forwardPE": -0.005813954, "priceToBook": 250.0, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1628665200000, "priceHint": 2, "regularMarketChange": 0.0, "regularMarketDayHigh": 0.0, "regularMarketDayRange": "0.0 - 0.0", "regularMarketDayLow": 0.0, "regularMarketVolume": 81872, "regularMarketPreviousClose": 15.0, "bid": 14.0, "ask": 16.0, "fullExchangeName": "LSE", "financialCurrency": "GBP", "regularMarketOpen": 0.0, "averageDailyVolume3Month": 43627, "averageDailyVolume10Day": 10427, "fiftyTwoWeekLowChange": 15.0, "fiftyTwoWeekRange": "0.0 - 24.7", "fiftyTwoWeekHighChange": -9.700001, "fiftyTwoWeekHighChangePercent": -0.39271256, "fiftyTwoWeekLow": 0.0, "fiftyTwoWeekHigh": 24.7, "symbol": "BVX.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Alderley Park", "address2": "Alderley Edge Cheshire", "city": "Macclesfield", "zip": "SK10 4TG", "country": "United Kingdom", "website": "https://www.bivictrix.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Ms. Tiffany Jane Thorn BSc. MSc., M.Sc.", "age": 34, "title": "CEO & Exec. Director", "yearBorn": 1988, "fiscalYear": 2022, "totalPay": {"raw": 192500, "fmt": "192.5k", "longFmt": "192,500"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alex  Hughes", "title": "Chief Financial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Simon  Wallwork", "title": "Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}